Companies don't have to be big to be bought out, they just need an innovative product that bigger companies need. CVSL may have that.
CVSL holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures.
Make sure CVSL is on your watch list. If you yahoo to look up the quote, make sure you at .ob to the ticker: CVSL.ob
A heart attack occurs about every 20 seconds with a heart attack death about every minute.
Every 20 seconds! Wow, this is very scary.
CVSL's technology could one day be used by all the heart surgeons in the world.
This technology could save millions of lives.
CVSL CEO Eli Gonen stated, "Cardio Vascular Medical Device has developed a technology that provides several advantages over the current guidewires being employed in angioplasty procedures."
Angioplasty is a common procedure that is performed to widen narrowed or obstructed blood vessels. The procedure is often performed in place of, or before a more invasive and potentially life-threatening bypass surgery is needed.
More than seven million angioplasties are performed worldwide each year!
Angioplasty that is performed before an artery is fully-blocked can prevent the onset of heart attacks.
"With well over 7 million angioplasties performed each year, the global annual potential addressable market exceeds $500 million," CVSL CEO Eli Gonen stated.
CVSL holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures.
Heart disease kills more woman every year than all cancers combined! According to the World Health Organization, some 7.2 million men and women die as a result of cardiac heart disease. Heart disease is the leading cause of death for both women and men in the United States.
CVSL's technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.
CVSL has an opportunity to become the gold standard as the guidewire of choice for heart surgeons throughout the world!
CVSL Advantages are:
CVSL Improved performance
Faster use, enabling the neurosurgeon to reach the desired location
Controlled bending angle
Easy to use handle
Quick detachment from the operating handle
Available in all ongoing sizes
Cost efficiency for patient and a health care providers
CVSL Operating Principles:
Coated coiled spring includes a wire which is attached to both ends of the spring.
Coils near the tip are spread apart.
One side is filled with a coating plastic material which allows the tip of the coiled springs, when pulled, to bend into the unfilled direction.
The tip is bent by pulling back the wire.
Spreading the spring coils apart, in the proximal end, by the handle, pushes the wire back causing it to pull the tip.
CVSL is is working diligently to complete the development of the guidewire, in preparation for full commercial distribution!!
CVSL has decided to initiate patent applications in Europe, Canada and the Far East for its proprietary next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures.
CVSL CEO Eli Gonen commented, "Filing these additional patent applications is the first stage in aiding cardiologists in the process of saving lives across the globe.
"The ability to steer our guidewire during angioplasty procedures using our patented flexi-tip enables more difficult procedures to be completed with greater ease, and speeds overall procedure time," Gonen added.
For more information on CVSL visit their website at: http://www.cvslmedical.com Make sure you always do your own research and consult with your own financial professional.
No comments:
Post a Comment